{"entity":{"id":"nct06654440","kind":"trial","name":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","aka":[],"tldr":"A phase 2 trial of SHR-A2102 in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy is a phase 2 interventional study registered as NCT06654440 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 100 participants planned, started 2024-11-15 and due to reach its primary completion in 2025-08-31. Interventions recorded: SHR-A2102 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06654440","url":"https://clinicaltrials.gov/study/NCT06654440"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-a2102"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06654440","phase":"2","setting":"An Open-label, Multicenter Phase II Clinical Study of SHR-A2102 for Injection in the Treatment of Advanced Gynaecological Malignancies","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct06654440/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}